Regístrese
Buscar en
Progresos de Obstetricia y Ginecología
Toda la web
Inicio Progresos de Obstetricia y Ginecología Current status of ovarian cancer in the Spanish Province of Castellon. Prognosti...
Información de la revista
Vol. 57. Núm. 9.
Páginas 405-412 (Noviembre 2014)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
684
Vol. 57. Núm. 9.
Páginas 405-412 (Noviembre 2014)
Original article
DOI: 10.1016/j.pog.2014.05.007
Acceso a texto completo
Current status of ovarian cancer in the Spanish Province of Castellon. Prognostic factors in observed and relative survival. A population cancer-registry-based study between 2004 and 2008
Estado actual del cáncer de ovario en la provincia de Castellón. Factores pronósticos en la supervivencia observada y relativa. Un estudio basado en registros poblacionales de cáncer de entre 2004 y 2008
Visitas
684
Jose Antonio Llueca Abellaa,
Autor para correspondencia
antonillueca@gmail.com

Corresponding author.
, David Martinez-Ramosb, Javier Escrig-Sosb, Ana Torrella-Ramosc, Jose Luis Herraiz Rodaa, Ana Serra Ruberta, Raquel Queralt-Martínb, Jose Luis Salvador-Sanchisb, Enrique Calpe Gomeza
a Department of Obstetrics and Gynecology, General University Hospital of Castellon, Spain
b Department of General and Digestive Surgery, General University Hospital of Castellon, Spain
c Castellón Cancer Registry, Conselleria de Sanitat, Spain
Este artículo ha recibido
684
Visitas
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (3)
Mostrar másMostrar menos
Tablas (3)
Table 1. Tumor characteristics according to year of incidence.
Table 2. Cumulated probability of survival: Observed and Relative survival by years of follow-up.
Table 3. Observed and Relative survival: univariate and multivariate analyses.
Mostrar másMostrar menos
Abstract
Background

The aim of this population-based study was to assess independent prognostic factors in ovarian cancer by analyzing observed and relative survival in a representative Spanish population.

Methods

We carried out a retrospective, observational, population-registry-based study. Data on 207 patients with ovarian cancer were provided by the Castellon Cancer Registry. Observed and relative survival were described at 1, 3 and 5 years. The effect of prognostic factors on survival was assessed with univariate and multivariate analyses.

Results

The median follow-up was 40.8 months (range: 12–108 months). Observed and relative survival rates at 1, 3 and 5 years were 79%, 51%, 33%, and 84%, 58%, 40%, respectively. Age older than 70 years showed worse observed survival in the univariate and multivariate analyses. Only FIGO stage was an independent prognostic factor for observed and relative survival.

Conclusions

Survival is poor in patients with ovarian cancer. In our population-registry-based study, only age at diagnosis and FIGO stage were independent prognostic factors for observed survival, whereas only FIGO stage could be considered a prognostic factor for relative survival.

Keywords:
Ovarian cancer
Survival
Prognosis
Cancer registry
Resumen
Antecedentes

El objetivo de este estudio poblacional fue evaluar los factores pronósticos independientes de cáncer de ovario mediante el análisis de la supervivencia observada y relativa en una población española representativa.

Métodos

Se realizó un estudio retrospectivo, observacional, y basado en un registro de población. Los datos de 207 pacientes con cáncer de ovario proceden del Registro de Cáncer de Castellón. Se describió la supervivencia observada y relativa a 1, 3 y 5 años. El efecto de los factores pronósticos en la supervivencia se evaluó mediante análisis univariantes y multivariantes.

Resultados

La mediana de seguimiento fue de 40,8 meses (intervalo: 12-108 meses). Las tasas de supervivencia observada y relativa a 1, 3 y 5 años fueron de 79%, 51% y 33% y de 84%, 58% y 40%, respectivamente. La edad superior a los 70 años mostró la peor supervivencia observada en los análisis univariantes y multivariantes. Sólo el estadio en la clasificación FIGO fue un factor pronóstico independiente de la supervivencia observada y relativa.

Conclusiones

La supervivencia en los pacientes con cáncer de ovario es limitada. En nuestro estudio basado en un registro de población, sólo la edad en el momento del diagnóstico y el estadio de FIGO fueron factores pronósticos independientes para la supervivencia observada, mientras que sólo el estadio de la FIGO se podría considerar un factor pronóstico en la supervivencia relativa.

Palabras clave:
cáncer de ovario
Supervivencia
Pronóstico
Registro de cáncer
Texto completo
Introduction

Ovarian cancer accounts for 5% of all cancers among women and causes more deaths than any other female genital tract cancer. In Spain (Europe) approximately 8/100,000 habitants will develop ovarian cancer. Ovarian cancer is often diagnosed at an advanced stage, and about 70–80% of them will be found at an advanced stage. For this group of patients 5-year-survival is lower than 20%.1

Several prognostic factors for ovarian cancer have been studied and reported in an attempt to increase tumor-free survival.2,3 The most important and constant prognostic factors reported have been International Federation of Gynecology and Obstetrics (FIGO) stage, size of residual tumor after primary surgery and age at diagnosis. Other variables, such as time period, histological type and grade, performance status, preoperative CA 125 levels or other molecular markers seem not to be so predictive.4–6

The main objective of this population registry cancer-based study was to evaluate prognostic factors for ovarian cancer survival in the European Province of Castellon (Spain) during the period 2004–2008.

Methods

The Province of Castellon is located in the Comunitat Valenciana at the Mediterranean coast in the East of Spain (Europe). The population of Castellon officially reached 604,333 people in 2011, as recorded by the National Statistics Institute of Spain. Although most patients with ovarian cancer are treated in the Castellon University General Hospital – where this study was conducted – there are also 3 public hospitals and 1 private hospital in this province.

According to the Castellon Cancer Registry, follow-up period was since 1 January 2004 to 31 December 2012. The Castellon Cancer Registry Database was used to identify eligible ovarian cancer patients. This population cancer registry is included in the EUROCARE study. Out of a total of 236 patients with ovarian cancer in the database diagnosed between 1 January 2004 and 31 December 2008, there were 207 finally analyzed due to excessive missing data in 29 cases. Patients without histological confirmation and those with borderline cancers or cancers with a low malignant potential were excluded. The incidence rate was adjusted to standard world's population and it is reported as the new diagnosed cases per 100,000 person-year.7

The following available variables were studied: age at diagnosis, FIGO stage,1 histology and grade of differentiation (according to the WHO classification).8 For this study, histological types were grouped in several groups according to a condensed IARC-classification.9 The data analysis was approved by our Ethical and Clinical Investigation Committee.

Statistical analysis

Quantitative variables were defined as median and range. Qualitative variables were described as frequency and percentages. To calculate Expected survival for a similar population without ovarian cancer Ederer's method was used adjusting women's mortality tables by age and year in the Comunitat Valenciana for the period 2004–2008, obtained from the National Statistics Institute of Spain. Observed survival was defined as time between diagnosis and date of death of a patient for any cause and was calculated using Kaplan–Meier actuarial method. The Relative survival is the ratio between Observed survival and Expected survival. A Cox proportional hazard model10 was used for multivariate analysis of Observed survival. Univariate analysis of Observed survival was performed using also this method but including only one variable. According to Dickman,11 a generalized linear model with a Poisson error structure was used for multivariate analysis of Relative survival. This model has been previously used by others.12 Univariate analysis of Relative survival was performed using also this method but including only one variable.

All tests were two-tailed and the level of p<0.05 was considered statistically significant. STATA for Windows, version 12 (StataCorp, College Station, TX) was used to perform the statistical analyses.

Results

Two hundred and seven patients were included in the study (Codes C56, C57.0-4 from International Classification of Disease, ICE-10). The median age at diagnosis was 65 years (range: 22–98). Diagnosis was established by means of histological analysis of primary tumor in 161 cases (77.8%), histological analysis of metastases in 7 cases (3.4%), diagnostic imaging in 20 cases (9.6%), cytology in 11 cases (5.3%) and death certificate in 8 patients (3.9%). A total of 186 cases (89.9%) presented as a primary tumor without metastasis, in 8 cases (3.9%) it was a secondary tumor. Median of the total number of tumors was 1 (range 1–3).

Median follow-up time was 40.8 months (range 12–108 months). A total of 151 patients died during the follow-up (73%). The median overall Observed survival was 49% (range: 21–96%), whereas Relative survival was 56% (range: 26–96%). The incidence of cases by year is detailed in Table 1. Cumulative probability of Observed and Relative survival at 1, 3 and 5 years of follow-up is shown in Table 2. Standardized incidence rate by age and year is shown in Fig. 1A. Observed and Relative survival curves (including 95% confidence interval) are shown in Fig. 1B and C, respectively.

Table 1.

Tumor characteristics according to year of incidence.

Year of incidence  2004  2005  2006  2007  2008  Total 
Grade
2 (22)  4 (45)  2 (22)  1 (11)  9 (4) 
II  4 (30)  2 (14)  2 (14)  3 (21)  3 (21)  14 (7) 
III  14 (32)  12 (27)  6 (14)  3 (7)  9 (20)  44 (21) 
Unknown  24 (17)  29 (21)  30 (21)  27 (19)  30 (21)  140 (68) 
Age
<50  13 (30)  9 (20)  9 (20)  7 (16)  6 (14)  44 (21) 
50–70  18 (21)  19 (23)  16 (19)  15 (18)  16 (19)  84 (41) 
70+  13 (16)  19 (24)  13 (16)  13 (16)  21 (28)  79 (38) 
Histology
Serous  15 (21)  16 (22)  11 (15)  11 (15)  20 (27)  73 (36) 
Mucinous  5 (41)  1 (8)  2 (17)  2 (17)  2 (17)  12 (6) 
Endometroid  2 (12)  4 (24)  4 (24)  5 (28)  2 (12)  17 (8) 
Clear cells  1 (20)  2 (40)  1 (20)  1 (20)  5 (2) 
Others/non specified  21 (21)  24 (24)  20 (20)  17 (17)  18 (18)  100 (48) 
FIGO stage
9 (35)  4 (15)  3 (12)  5 (19)  5 (19)  26 (13) 
II  1 (10)  3 (27)  2 (18)  2 (18)  3 (27)  11 (5) 
III  14 (18)  17 (22)  10 (13)  13 (17)  23 (30)  77 (37) 
IV  8 (15)  17 (32)  12 (23)  8 (15)  8 (15)  53 (26) 
Non specified  12 (30)  6 (15)  11 (28)  7 (18)  4 (10)  40 (19) 
Total  44 (21)  47 (23)  38 (18)  35 (17)  43 (21)  207 

Frequencies (rounded %).

Table 2.

Cumulated probability of survival: Observed and Relative survival by years of follow-up.

  Observed/Relative
  1 year  3 years  5 years 
Global  0.79/0.84  0.51/0.58  0.33/0.40 
Grade
0.89/0.91  0.77/0.84  0.55/0.60 
II  0.85/0.92  0.57/0.66  0.50/0.61 
III  0.88/0.92  0.54/0.59  0.29/0.32 
Unknown  0.75/0.80  0.53/0.63  0.40/0.52 
Age
<50  0.85/0.86  0.61/0.62  0.46/0.47 
50–70  0.82/0.84  0.59/0.64  0.45/0.51 
>70  0.76/0.90  0.43/0.66  0.21/0.40 
Histology
Serous  0.85/0.90  0.52/0.59  0.35/0.43 
Mucinous  0.75/0.78  0.41/0.46  0.33/0.40 
Endometroid  0.94/0.97  0.88/0.94  0.55/0.62 
Clear cells  0.80/0.83  0.80/0.83  0.40/0.47 
Others/non specified  0.73/0.79  0.50/0.60  0.38/0.50 
FIGO stage
0.92/0.96  0.81/0.91  0.71/0.85 
II  0.82/0.86  0.63/0.72  0.53/0.62 
III  0.80/0.86  0.52/0.60  0.29/0.35 
IV  0.59/0.64  0.18/0.22  0.05/0.06 
Non specified  0.91/0.96  0.82/0.95  0.72/0.90 
Figure 1.

Standardized incidence rates by age and years (A). General cumulated probability of survival, Relative (B) and Observed (C).

(0,31MB).

Figs. 2 and 3 show Observed and Relative survival curves according to available variables. As seen in these figures, the groups with a worse prognosis were age over 70 years, histological grade III, serous tumors and stage IV. On univariate analysis for Observed survival (Table 3), age over 70 years showed statistically significant differences compared with patients under 50 years. Statistically significant differences were also seen for patients in stage III and IV comparing with stage I. On multivariate analysis for Observed survival, age at diagnosis and stage showed both statistically significant differences. On multivariate analysis for Relative survival, the excess of mortality was approximately five times higher among stage III and twelve times higher among patients with stage IV comparing with stage I.

Figure 2.

Cumulated probability of Relative survival and Observed survival by age groups (A and B), and FIGO stages (C and D).

(0,36MB).
Figure 3.

Cumulated probability of Relative survival and Observed survival by histological grade (A and B), and histology (C and D).

(0,37MB).
Table 3.

Observed and Relative survival: univariate and multivariate analyses.

  Observed survivalRelative survival
  UnivariateMultivariateUnivariateMultivariate
  H. ratio  95% CI  p  H. ratio  95% CI  p  H. ratio  95% CI  p  H. ratio  95% CI  p 
Grade
Reference      Reference      Reference      Reference     
II  1.52  0.45–5.05  0.492  1.21  0.34–4.32  0.764  1.46  0.35–6.12  0.599  1.95  0.36–10.5  0.436 
III  2.03  0.71–5.75  0.181  0.88  0.29–2.70  0.835  2.24  0.66–7.56  0.194  1.60  0.35–7.26  0.537 
Unknown  1.90  0.69–5.24  0.213  1.40  0.47–4.13  0.541  2.24  0.68–7.39  0.184  2.18  0.50–9.41  0.296 
Age
<50  Reference      Reference      Reference      Reference     
50–70  1.13  0.68–1.89  0.613  1.18  .073–1.92  0.479  1.12  0.66–1.90  0.652  0.88  0.51–1.50  0.642 
>70  1.86  1.10–3.15  0.020  2.11  1.30–3.42  0.002  1.55  0.86–2.82  0.143  0.98  0.53–1.84  0.971 
Histology
Serous  Reference      Reference      Reference      Reference     
Mucinous  1.03  0.49–2.18  0.938  1.48  0.68–3.21  0.315  0.90  0.37–2.19  0.819  2.07  0.85–5.04  0.105 
Endometroid  0.49  0.22–1.09  0.002  0.79  0.34–1.83  0.594  0.52  0.22–1.21  0.132  0.88  0.35–2.23  0.797 
Clear cells  0.72  0.22–2.34  0.000  0.71  0.21–2.36  0.582  0.62  0.16–2.42  0.498  1.17  0.30–4.55  0.812 
Others/non spec.  1.02  0.66–1.57  0.862  1.75  1.20–2.54  0.003  1.08  0.66–1.76  0.740  1.41  0.86–2.30  0.166 
FIGO stage
Reference      Reference      Reference      Reference     
II  2.02  0.70–5.84  0.193  2.08  0.70–6.15  0.183  2.32  0.61–8.75  0.213  3.16  0.74–13.4  0.117 
III  3.18  1.50–6.72  0.002  3.59  1.67–7.69  0.001  3.86  1.46–10.2  0.006  4.67  1.56–13.9  0.006 
IV  7.02  3.18–15.5  0.000  7.57  3.40–16.8  0.000  11.2  4.20–29.7  0.000  12.9  4.17–39.6  0.000 
Non specified  1.09  0.40–2.90  0.862  2.28  0.99–5.21  0.051  1.17  0.32–4.23  0.804  1.08  0.27–4.34  0.907 
Discussion

This study has included all the cases of invasive ovarian cancer diagnosed in the Spanish Province of Castellon during 2004–2008. The incidence rate of ovarian cancer in our province can be considered as intermedium-low when it is compared with other population cancer registries, in our country or internationally.13,14

Survival analysis showed that both Observed and Relative survival progressively decreases at 3 and 5 years of follow-up. Observed survival was 51% and 33%, whereas relative survival was 58% and 40%, respectively. These data indicate similar survival than the rest of Spain (relative 5-year survival 39%), similar to data reported in EUROCARE from other countries in Europe (relative 5-year survival 41%) and a little below the United States of America.15,16

Age at diagnosis has been repeatedly reported as an independent risk factor for ovarian cancer.3,17–22 In fact, patients over 70 years in our study showed almost two times greater chance of death than patients under 50 years. It is probable, that comorbidities (heart problems, hypertension, diabetes, etc.) in this group of older patients affect the prognosis for two main reasons. On the one hand, it is possible that an aggressive treatment cannot be withstood by weak patients, affecting directly their survival. On the other hand, it is possible that treatments applied in these patients were given in a less aggressive or uncompleted way, what could also affect their potential benefit. Nevertheless, in our study, Relative survival, having into account the Spanish characteristics, demonstrated that age at diagnosis is not an independent risk factor. In consequence, it could be assumed that tumor aggressiveness is similar in any age of diagnosis.

When the grade of differentiation of the tumor was analyzed, not statistically significant differences were found. These results are in agreement with those of other authors and could be explained by a known inter-observer variability when establishing the degree of differentiation of a tumour.23,24

Serous tumors have been reported to have a worse prognosis that other epithelial tumours.13,25 However, our study did not reach statically significance in analysis for histological type. Only for Observed survival in univariate analysis some differences were found. It is possible, that the relatively low number of cases could explain these paradoxical results.

As it is well known, ovarian cancer is diagnosed frequently at an advanced stage. In fact, near 60% of the patients in our population were diagnosed in FIGO stage III and IV, whereas only a minority of these tumors (18%) was diagnosed in an early stage. For early ovarian cancer, Observed survival was similar to those reported for other authors. Nevertheless, for advanced stages, the survival of our population was worse than in other western countries. For FIGO stage IV, 5-year survival was 0.05%, that is, close to zero. As a consequence, FIGO stage was confirmed in our study as the main important independent risk factor for survival, both in univariate and multivariate analyses. This results are also in concordance with those reported by other authors.26,27 Early diagnosis is one of the main objectives of population cancer care. Moreover, it is possible that a significant increase on population survival reflects an earlier diagnosis. There is not an effective population screening program in ovarian cancer, but it is known that many patients may benefit from ultrasound diagnosis and tumor markers levels, such as CA 125, in order to anticipate diagnosis. Consequently, this early diagnosis could improve survival for a very important group of patients.28 Although our population-based study reflects that only 18% of patients are diagnosed in an early stage, we believe that this percentage will be increased in the following years for two main reasons. First, access to the health system is becoming increasingly frequent, and second new technologies such as image tests and laparoscopic approaches to abdominal cavity may diagnose cancers in earlier stages.

Another important prognostic factor in ovarian cancer is residual tumor after cytoreductive surgery. In fact, among patients undergoing operative intervention for ovarian cancer, the proportion of patients undergoing complete cytoreductive surgery is independently associated with overall survival time.29 Unfortunately, our study was not able to determine this relationship, since this variable was not available from our population registry.

It is important to emphasize that only population-based studies can demonstrate independent prognostic factors that can affect the entire population. Therefore, this is the only reliable way to analyze which is the impact of these risk factors on survival. One of the main strengths of our study is that this population-registry cancer study includes data from several institutions in our province, and not from a single institution. As a consequence, it reflects our reality better than studies conducted in very specialized institutions. Moreover, in contrast to clinical studies, in which patients are selected, population-based studies are based upon a heterogeneous group of patients and can be used to determine prognostic factors with low risk of selection bias. As a consequence, it is highly likely that our findings reflect what really happened in Spain during the period study 2004–2008.

Conclusion

Patients with ovarian cancer present a poor survival. In our population registry-based study, only age at diagnosis and FIGO stage were independent prognostic factors for observed survival, whereas only FIGO stage can be considered a prognostic factor for relative survival.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Ethical responsibilities

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

References
[1]
S. Pecorelli, J.L. Benedet, W.T. Creasman, J.H. Shephard, F. Pettersson.
International Federation of Gynecology and Obstetrics, (1998),
[2]
S. Tingulstad, F.E. Skjeldestad, T.B. Halvorsen, B. Hagen.
Survival and prognostic factors in patients with ovarian cancer.
Obstet Gynecol, 101 (2003), pp. 885-891
[3]
W.E. Winter, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, P.G. Rose, et al.
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
J Clin Oncol, 25 (2007), pp. 3621-3627
[4]
T.G. Clark, M.E. Stewart, D.G. Altman, H. Gabra, J.F. Smyth.
A prognostic model for ovarian cancer.
Br J Cancer, 85 (2001), pp. 944-952
[5]
C.T. Griffith.
Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.
Natl Cancer Inst Monogr, 42 (1975), pp. 101-104
[6]
B. Lund, P. Williamson.
Prognostic factors for overall survival in patients with advanced ovarian carcinoma.
Ann Oncol, 2 (1991), pp. 281-287
[7]
N.E. Breslow, N.E. Day.
Statistical methods in cancer research Volume II—the design and analysis of cohort studies.
IARC Sci Publ, 82 (1987), pp. 1-406
[8]
R.E. Scully, L.H. Sobin, et al.
Histological typing of ovarian tumors.
2nd ed., WHO, (1999),
[9]
D.M. Parkin, V.W. Chen, J. Ferlay, J. Galceran, H. Storm, S. Whelan.
Comparability and quality control in cancer registration.
International Agency for Research on Cancer, (1994),
[10]
D.R. Cox.
Regression models and life-tables.
J R Stat Soc, 34 (1972), pp. 187-220
[11]
P.W. Dickman, A. Sloggett, M. Hills, T. Hakulinen.
Regression models for relative survival.
Statis Med, 23 (2004), pp. 51-64
[12]
Z. Hamidou, S. Causeret, T.S. Dabakuyo, J. Gentil, L. Arnould, P. Roignot, et al.
Population-bases study of ovarian cancer in Côte-D’Or: prognostic factors and trends in relative survival rates over the last 20 years.
BMC Cancer, 10 (2010), pp. 622-630
[13]
J.A. Llueca.
Epidemiologia de las neoplasias malignas de ovario en Tarragona, 1980–2005.
Tesis doctoral en Medicina, Universitsat Rovira i Virgili, (2012),
[14]
pp. 155
[15]
F. Berrino, A.R. De, M. Sant, S. Rosso, M. Bielska-Lasota, J.W. Coebergh, et al.
Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study.
Lancet Oncol, 8 (2007), pp. 773-783
[16]
SEER Cancer Statistics Review, 1975–2008,
[17]
D. Pectasides, G. Papaxoinis, G. Fountzilas, G. Aravantinos, A. Bamias, N. Pavlidis, et al.
Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG).
Anticancer Res, 29 (2009), pp. 745-751
[18]
E.A. Tracey, D.M. Roder, J. Francis, H.M. Zorbas, N.F. Hacker, J.F. Bishop.
Reasons for improved survival from ovarian cancer in New South Wales Australia, between 1980 and 2003: implications for cancer control.
Int J Gynecol Cancer, 19 (2009), pp. 591-599
[19]
J.K. Chan, D. Teoh, J.M. Hu, J.Y. Shin, K. Osann, D.S. Kapp.
Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types?. A study of 1411 clear cell ovarian cancers.
Gynecol Oncol, 109 (2008), pp. 370-376
[20]
G.D. Malkasian, L.J. Melton, P.C. O’Brien, M.H. Greene.
Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary.
Am J Obstet Gynecol, 149 (1984), pp. 274-284
[21]
K.D. Swenerton, T.G. Hislop, J. Spinelli, J.C. LeRiche, N. Yang, D.A. Boyes.
Ovarian carcinoma: a multivariate analysis of prognostic factors.
Obstet Gynecol, 65 (1985), pp. 264-270
[22]
H.R. Balvert-Locht, J.W.W. Coebergh, W.C.J. Hop, H.A.M. Bro??lmann, M. Crommelin, D.J.A.M. van Wijck, et al.
Improved prognosis of ovarian cancer in the Netherlands during the period 1975–1985: a registry-based study.
Gynecol Oncol, 42 (1991), pp. 3-8
[23]
J.P.A. Baak, F.A. Langley, A. Talerman, J.F.M. Delemarre.
The prognostic variability of ovarian tumor grading by different pathologists.
Gynecol Oncol, 27 (1987), pp. 166-172
[24]
H. Stalsberg, V. Abeler, G.P. Blom, L. Bostad, E. Skarland, G. Westgaard.
Observer variation in histologic classification of malignant and borderline ovarian tumors.
Hum Pathol, 19 (1988), pp. 1030-1035
[25]
T. Bjorge, A. Engeland, S. Hansen, C.G. Trope.
Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993.
Int J Cancer, 75 (1998), pp. 663-670
[26]
SEER Cancer Statistics Review, 1975–2010,
[27]
S. Tingulstad, F.E. Skjeldestad, T.B. Halvorsen, B. Hagen.
Survival and prognostic factors in patients with ovarian cancer.
Obstet Gynecol, 101 (2003), pp. 885-891
[28]
A. Kjaerbye-Thygesen, L.D. Huusom, K. Frederiksen, S.K. Kjaer.
Trends in the incidence and mortality of ovarian cancer in Denmark 1978–2002. Comparison with other Nordic countries.
Acta Obstet Gynecol Scand, 84 (2005), pp. 1006-1012
[29]
R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, F.J. Montz.
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
J Clin Oncol, 20 (2002), pp. 1248-1259
Copyright © 2014. SEGO
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.